Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897723 | 0.75 | NPC1 (0.40) | RAB9ANPC1KDM4EALDH1A1MAPT | |
| SCHEMBL27636509 | 0.74 | BTK (0.43) | BTKRAB9ANPC1L3MBTL1HDAC6 | |
| SCHEMBL2752572 | 0.73 | MGAM (0.52) | RAB9ANPC1KDM4EALDH1A1MAPT | |
| SCHEMBL2903111 | 0.71 | DHODH (0.34) | HDAC6PDE10A | |
| SCHEMBL22940960 | 0.71 | PDE10A (0.53) | BTKRAB9ANPC1L3MBTL1PDE10A | |
| SCHEMBL23292536 | 0.70 | KDM4E (0.60) | BTKRAB9ANPC1L3MBTL1KDM4E | |
| SCHEMBL2902890 | 0.70 | KCNN4 (0.35) | RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL2903039 | 0.69 | — | — | |
| SCHEMBL2895375 | 0.68 | CYP19A1 (0.34) | CLK4CYP19A1 | |
| SCHEMBL13422264 | 0.68 | DHODH (0.53) | BTKRAB9ANPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | BTK 1129/4885RAB9A 1331/4885NPC1 154/4885 |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | BTK 1129/4885RAB9A 1331/4885NPC1 154/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | BTK 1129/4885RAB9A 1331/4885NPC1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.